EC Healthcare First Half 2024 Earnings: EPS: HK$0.006 (vs HK$0.068 in 1H 2023)

Simply Wall St

December 03, 2023

EC Healthcare (HKG:2138) First Half 2024 Results

Key Financial Results

Revenue: HK$2.12b (up 12% from 1H 2023).
Net income: HK$6.65m (down 92% from 1H 2023).
Profit margin: 0.3% (down from 4.2% in 1H 2023).
EPS: HK$0.006 (down from HK$0.068 in 1H 2023).

earnings-and-revenue-growth — SEHK:2138 Earnings and Revenue Growth December 3rd 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

EC Healthcare Earnings Insights

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Consumer Services industry in Hong Kong.

Performance of the Hong Kong Consumer Services industry.

The company's shares are down 11% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for EC Healthcare you should know about.

If you're looking to trade EC Healthcare, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if EC Healthcare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.